创美药业2024年年度报告

ANNUAL REPORT CharmacyPharmaceutical Co., Ltd. (stock code: 2289.HK) isprincipally engaged in the pharmaceutical distribution business.It mainly distributes western medicine, Chinese patent medicineand healthcare products to downstream distributors and retailterminals,while conducting dealings in the third-party logisticsbusiness of medicines and providing pharmaceutical productsrelated consulting services. Founded in 2000, over the past25years of rapid development, it has become one of the leadingpharmaceutical distributors in the Southern China region. TheCompany adheres to the development strategy of “IntensiveEngagement in Guangdong Province and Extensive Coverageacross Surrounding Areas”, based in Shantou, it has establishedsubsidiariesin Guangzhou,Zhuhai,Huizhou,Foshan andShenzhen, and has four modern pharmaceutical logistics centers.,allequipped with Professional marketing service team,professional transportation teams, and has a highly efficientdelivery mechanism of delivering pharmaceutical products threetimes per day for customers within a radius of 10 kilometers,twice per day for customers within a radius of 50 kilometers andonce per day for those within a radius of 250 kilometers. Inaddition, the Company has a modern information system thatcovers the entire supply chain for pharmaceutical distribution,including procurement, sales, warehousing, transportation anddelivery. Apart from that, the Company operates its own B2B e-commerce platform “Charmacy e-Medicine” (創 美e藥), aplatform for customers to place orders online, make inquires andpayment ,etc. In 2023, the Company ranked top35 among top100thePRC wholesalers, in respect of revenue generated fromthe principal business. The Company ranked the 6th among thepharmaceutical distributionbusinesses in Guangdong Province. 創美藥業股份有限公司（股份代號：2289.HK）主營醫藥分銷業務，主要向下游分銷商和零售終端分銷西藥、中成藥、保健品等產品，同時也開展第三方物流服務，並提供醫藥產品諮詢服務。本公司創立於2000年，經過25年的快速發展，已成長為華南地區領先的醫藥分銷商之一。本公司堅持「深耕廣東，輻射周邊」的發展戰略，立足於汕頭，在廣州、珠海、惠州、佛山及深圳成立子公司，並擁有四個現代化醫藥物流中心，專業的營銷服務團隊以及運輸服務團隊，對非招標市場實行「半徑10公里內一日三配、50公里內一日兩配、250公里內一日一配」的高效配送機制。本公司具有現代化信息系統，涵蓋整個醫藥分銷供應鏈，包括採購、銷售、倉儲、運輸及交付等。本公司同時運營自建的B2B電子商務平台：「創美e藥」，供客戶線上下單、查詢及支付等。本公司於2023年全國批發企業主營業務收入前100位排序35。本公司於廣東省醫藥流通企業排名第6位。 2024年，依托出色的倉儲配送體系，本集團新獲得由藥鏈圈認證中心頒發的2023-2024年度醫藥物流配送優秀企業（連續4年獲得）、2023-2024年度現代醫藥物流技術試驗基地 （ 中 心 ） （ 連 續3年 獲 得 ） 、2023-2024年度醫藥冷鏈最佳物流中心 （ 基 地 ） （ 連 續6年 獲 得 ） 、2023-2024年度醫藥冷鏈物流服務推薦企業（連續5年獲得），2023- In 2024, relying on the excellent warehouse distribution system,theGroup was recognised as an Excellent PharmaceuticalLogisticsand Distribution Enterprise in 2023–2024(for 4consecutiveyears),a Modern Pharmaceutical LogisticsTechnology Test Base (Centre) in 2023–2024 (for 3 consecutiveyears), the Best Pharmaceutical Cold Chain Logistics Centre(Base) in 2023–2024 (for 6 consecutive years), a RecommendedEnterprise for Pharmaceutical Cold Chain Logistics Services in2023–2024 (for 5 consecutive years), ranked among the top 50modern logistics service providers for pharmaceuticals in 2023- 2024年度藥品三方現代物流服務能力 排 名 前50（ 連 續 兩 年獲 得 ） ，2023-2024藥 品 供 應 鏈 試 驗 基地 ，2023-2024藥品器械供應鏈最佳服務商。獲得由中國（廣州）國際物流裝備與技術展會組委會頒發的2023-2024年度中國物流行業金螞蟻創新獎（連續7年獲得）。獲得由中國醫藥物資協會醫藥商業分會頒發的“現代醫藥物流儲運管理規範”團體標準試點單位，獲得由中國醫藥商業協會頒發的藥品流通信息統計工作先進單位。 2024(for 2 consecutive years), the 2023-2024Pilot Base forpharmaceutical supply chain, and the best service provider forthe 2023-2024 pharmaceutical equipment supply chainby theYaolianquan Certification Centre.Awardedthe China LogisticsIndustry "GoldenAnt" Innovation Award in 2023–2024 by theOrganisingCommittee of China(Guangzhou)InternationalLogisticsEquipment and Technology Exhibition(for 7consecutive years).Obtained the group standard pilot unit of"ModernMedical Logistics Storage and TransportationManagement Norms" issued by the Pharmaceutical BusinessBranch of the China Medical Materials Association,andawardedtheexemplary organization of drug circulation informationstatistics by the China Pharmaceutical Commerce Association. 憑借良好的信譽與優質的服務，本公司獲得了由廣東省信用協會頒發的常務理事單位（連續7年獲得），獲得了由中國企業聯合會、中國企業家協會聯合頒發的2024年企業信用評價AAA級企業，2024年廣東省企業500强。 Dueto its good reputation and high-quality services,theCompany was awarded a Standing Council Member Unit by theGuangdong Credit Association (for 7consecutive years), grantedthe 2024 AAA-level Enterprise Credit Rating by the ChinaEnterprise Confederation and the China Enterprise DirectorsAssociation, and listed among the 2024 Guangdong Top 500Enterprises. 公司資料CORPORATEINFORMATION4主席報告CHAIRMAN’S STATEMENT6財務摘要FINANCIAL SUMMARY10管理層討論及分析MANAGEMENT DISCUSSION AND ANALYSIS11董事、監事及高級管理人員履歷BIOGRAPHIES OF DIRECTORS,SUPERVISORS AND SENIOR MANAGEMENT32企業管治報告CORPORATE GOVERNANCE REPORT42董事會報告DIRECTORS’ REPORT68監事會報告BOARD OF SUPERVISORS’ REPORT91審計報告AUDITOR’S REPORT94合併資產負債表CONSOLIDATED BALANCE SHEET101母公司資產負債表BALANCE SHEET OF THE PARENT COMPANY105合併利潤表CONSOLIDATED INCOME STATEMENT109母公司利潤表INCOME STATEMENT OF THEPARENT COMPANY112合併現金流量表CONSOLIDATED STATEMENT OF CASH FLOW114母公司現金流量表STATEMENT OF CASH FLOW OF THE PARENT COMPANY116合併股東權